SCHEMBL24253922

SCHEMBL24253922

O=C1CCCC2(CCN(c3cc(-c4ccc(F)cc4)n[nH]c3=O)CC2)N1c1ccc(F)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.36
MAPT P10636 3/20 0.35
TACR3 P29371 1/20 0.33
TP53 P04637 1/20 0.33
HTR1A P08908 4/20 0.33
DRD2 P14416 2/20 0.33
ADRA1D P25100 2/20 0.33
ADRA1A P35348 2/20 0.33
ADRA1B P35368 2/20 0.33
RET P07949 1/20 0.33
KDR P35968 1/20 0.33
MMP13 P45452 1/20 0.32
HTR7 P34969 2/20 0.31
HTR2B P41595 2/20 0.31
HTR6 P50406 2/20 0.31
HTR1D P28221 1/20 0.31
HTR3A P46098 1/20 0.31
CA12 O43570 1/20 0.31
ALPL P05186 1/20 0.31
RPA1 P27694 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424740 1.00 PARP1 (0.36) PARP1MAPTTACR3TP53HTR1A
SCHEMBL24253607 0.85 HTR1A (0.35) PARP1MAPTTP53HTR1ADRD2
SCHEMBL24253847 0.79 ADRA1D (0.33) PARP1HTR1ADRD2ADRA1DADRA1A
SCHEMBL24253732 0.78 USP2 (0.40) HTR1AHTR7HTR1DHTR3A
SCHEMBL26307799 0.78 PARP1 (0.31) PARP1HTR1ADRD2ADRA1DADRA1A
SCHEMBL30423965 0.77 EP300 (0.32) MAPTHTR1ADRD2ADRA1DADRA1A
SCHEMBL30423986 0.77 HTR1A (0.31) PARP1HTR1ADRD2ADRA1DADRA1A
SCHEMBL24253508 0.77 EP300 (0.32) MAPTHTR1ADRD2ADRA1DADRA1A
SCHEMBL24253504 0.77 HTR1A (0.31) PARP1HTR1ADRD2ADRA1DADRA1A
SCHEMBL24253930 0.73 GRM5 (0.33) HTR1ADRD2MMP13HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 PARP1 1434/4885MAPT 4450/4885TACR3 780/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 PARP1 1434/4885MAPT 4450/4885TACR3 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.